目的 探討澤桂癃爽膠囊聯(lián)合左氧氟沙星治療慢性前列腺炎的臨床療效。方法 選用回顧性病例對照研究方法，分析2021年2月—2023年11月首都醫(yī)科大學(xué)附屬北京友誼醫(yī)院平谷醫(yī)院收治的84例慢性前列腺炎患者的病例資料，按治療方案不同分為對照組和治療組，每組各42例。對照組口服左氧氟沙星片，0.5 g/次，1次/d。治療組在對照組治療基礎(chǔ)上口服澤桂癃爽膠囊，2粒/次，1次/d。兩組療程28 d。觀察兩組的臨床療效，比較兩組治療前后臨床表現(xiàn)評分、美國國立衛(wèi)生研究院慢性前列腺炎癥狀積分指數(shù)（NIH-CPSI）評分、癥狀自評量表（SCL-90）評分及前列腺按摩液（EPS）中白細(xì)胞（WBC）和卵磷脂小體（SPL）水平。結(jié)果 治療后，治療組總有效率是95.24%，顯著高于對照組的80.95%（P＜0.05）。治療后，兩組小便頻急評分、尿后余瀝不盡評分、尿道灼熱評分、會陰疼痛或不適評分、少腹疼痛或不適評分、腰骶部疼痛或不適評分均較同組治療前顯著降低（P＜0.05）；治療后，治療組臨床表現(xiàn)評分均低于對照組（P＜0.05）。治療后，兩組NIH-CPSI、SCL-90評分均顯著降低（P＜0.05）；治療后，治療組NIH-CPSI、SCL-90評分均顯著低于對照組（P＜0.05）。治療后，兩組EPS中WBC顯著降低，而EPS中SPL水平均顯著增加（P＜0.05）；治療后，治療組EPS中WBC和SPL水平改善優(yōu)于對照組（P＜0.05）。結(jié)論 澤桂癃爽膠囊聯(lián)合左氧氟沙星治療慢性前列腺炎具有較好的臨床療效，能有效抑制前列腺炎癥，促進(jìn)患者臨床表現(xiàn)減輕及身心健康狀態(tài)改善，值得推廣應(yīng)用。

Objective To explore the clinical efficacy of Zegui Longshuang Capsules combined with levofloxacin in treatment of chronic prostatitis. Methods A retrospective case-control study was used to analyze the case data of 84 patients with chronic prostatitis admitted to Pinggu Hospital, Beijing Friendship Hospital Affiliated to Capital Medical University from February 2021 to November 2023. They were divided into control and treatment groups according to different treatment plans, and each group had 42 cases. Patients in the control group were po administered with Levofloxacin Tablets, 0.5 g/time, once daily. Patients in the treatment group were po administered with Zegui Longshuang Capsules on the basis of the control group, 2 grains/time, once daily. Two groups were treated for 28 d. The clinical efficacy of two groups was compared, and the clinical manifestation score, National Institutes of Health Chronic Prostatitis Syndrome Score (NIH-CPSI) score, Symptom Self-rating Scale (SCL-90) score and the levels of white blood cells (WBC) and lecitin bodies (SPL) in prostate massage fluid (EPS) were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 95.24%, which was significantly higher than that of the control group (80.95%, P < 0.05). After treatment, the scores of rapid urination, incomplete urination, urethral burning, perineal pain or discomfort, low abdominal pain or discomfort, lumbosacral pain or discomfort were significantly lower in 2 groups than before treatment (P < 0.05). After treatment, the clinical performance score of the treatment group was lower than that of the control group (P < 0.05). After treatment, NIH-CPSI and SCL-90 scores were significantly decreased in both groups (P < 0.05). After treatment, NIH-CPSI and SCL-90 scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, WBC in EPS was significantly decreased, but SPL level in EPS was significantly increased in both groups (P < 0.05). After treatment, WBC and SPL levels in EPS in the treatment group were better than those in the control group (P < 0.05). Conclusion Zegui Longshuang Capsules combined with levofloxacin has good clinical effect in treatment of chronic prostatitis, and can effectively inhibit prostatic inflammation, promote the reduction of clinical manifestations and the improvement of physical and mental health status of patients, which is worthy of popularization and application.

R983